Analyst stock forecast
Metagenomi Therapeutics Forecast: $7.00 Analyst Target
MGX has a $7.00 target, Strong Buy rating and 3 analysts. As of 2026-08-17.
Direct answer
Metagenomi Therapeutics's average price target is $7.00.
The target implies +469.1% from the recorded current price, and the consensus rating is Strong Buy.
The low target implies +306.5%, the high target implies +631.7%, and the range spans 325.2% of the current price.
Forecast evidence checked August 17, 2026.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.23
- Average price target
- $7.00
- High price target
- $9.00
- Low price target
- $5.00
- Low target gap
- +306.5%
- Target upside
- +469.1%
- High target gap
- +631.7%
- Target range width
- 325.2%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 17, 2026
- Valid through
- August 24, 2026
Explore related company data
Read the frequently asked questions.
What is Metagenomi Therapeutics's average price target?
Metagenomi Therapeutics's verified average price target is $7.00. The target range is $5.00 to $9.00.
How far are Metagenomi Therapeutics's low and high targets from the recorded price?
The low target implies +306.5%, while the high target implies +631.7%.
How many analysts are included in Metagenomi Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Metagenomi Therapeutics's target upside or downside calculated?
The average target of $7.00 is divided by the recorded price of $1.23, then one is subtracted to produce +469.1%. This does not guarantee a future return.
When was Metagenomi Therapeutics's analyst forecast verified?
The data was verified on 2026-08-17. The dataset is valid through 2026-08-24.